Peptide Drugs intermediate
Denosumab: Oligopeptide Research Reference
RANKL inhibitor monoclonal antibody preventing osteoclast formation for bone density improvement. This peptide or oligopeptide is studied for its biological ...
By Encyclopeptide Editorial | 1 min read
rankl osteoporosis monoclonal-antibody
Overview
RANKL inhibitor monoclonal antibody preventing osteoclast formation for bone density improvement.
Structure
| Property | Value |
|---|---|
| Name | Denosumab |
Mechanism of Action
RANKL neutralization prevents osteoclast differentiation and activity.
References
- Wikipept Peptide Database
- Primary literature (see individual entries)
Chemical Identity
| Property | Value |
|---|---|
| Name | Denosumab |
| Category | Peptide Drugs |
Test Your Knowledge
Reinforce what you learned about Denosumab: Oligopeptide Research Reference with interactive quizzes on Wikipept.
Take a Quiz on Wikipept